Back to first-pass browser

First-pass extracted concept

in vivo HSC gene therapy

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This is an emerging strategy to treat sickle cell disease by delivering gene therapy directly in vivo to hematopoietic stem cells. The abstract specifically describes it as a single-injection HSC-targeted gene delivery concept.

Source 1DOIPubMed

Resources required

A key prerequisite is an HSC-targeted gene delivery system that can be administered in vivo. The abstract does not specify a particular delivery platform.

Source 1DOIPubMed

What problem it solves

It is being developed in response to the cost and complexity of established ex vivo HSC gene therapy workflows. The intended benefit is to simplify treatment delivery.

Source 1DOIPubMed

Alternatives

The abstract contrasts in vivo HSC gene therapy with established ex vivo autologous HSC gene therapy, hydroxyurea, and allogeneic HSC transplantation.

Source 1DOIPubMed

Evidence Snippets

in vivo HSC gene therapy is being developed to treat SCD, envisioning a single-injection HSC-targeted gene delivery system
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1comparative therapysupports2025Source 1DOIPubMed

Hydroxyurea is a first-line drug therapy for sickle cell disease but requires lifelong administration.

Quoted textsource-backed
Several drug therapies are available for SCD, including hydroxyurea, which is the first-line choice despite requiring lifelong administration.
Claim 2development directionsupports2025Source 1DOIPubMed

In vivo HSC gene therapy is being developed for sickle cell disease as a single-injection HSC-targeted gene delivery system.

Quoted textsource-backed
in vivo HSC gene therapy is being developed to treat SCD, envisioning a single-injection HSC-targeted gene delivery system
Claim 3disease suitabilitysupports2025Source 1DOIPubMed

Sickle cell disease is a prime candidate for gene therapy because it is a common single-gene disorder.

Quoted textsource-backed
Sickle cell disease is one of the most common single-gene disorders; therefore, SCD is a prime candidate for gene therapy.